Efficacy and safety of botulinum toxin type A for treatment of Frey's syndrome: evidence from 22 published articles

摘要: Frey's syndrome (FS) is an unavoidable sequela following the surgery of parotid gland. Although several treatment methods are available, their efficacy short term or accompanied by unacceptable complications. In past two decades, botulinum toxin type A (BTXA) has been widely used to treat FS. systematic reviews have reported recently, they were conflicting and with obvious deficiencies. Thus, we performed objectively review determine whether BTXA effective safe for literature retrieval covering PubMed, Web Science, Ovid, Embase Cochrane library was on 16 January, 2015. Proportion meta-analysis corresponding 95% confidence interval (CI) evaluate safety BXTA in total 499 records retrieved 22 articles 23 studies included after scrutiny independent authors. Statistical analyses regarding rate, incidence complications estimate BTXA. Our results suggested that rate FS 98.5% (95% CI = 0.971-0.994) complication 3.6% 0.017-0.061). conclusion, our study supports produces meaningful benefits patients However, owing lack strong evidence, future well-designed inclusion criteria multicenter randomized controlled trials needed give more credible if possible.